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ABSTRACT 
 
The Affect of All-trans Retinoic Acid and Fatty Acids on MCF-7 Breast Cancer Cell 
Progression 
iv 
 
By 
 
David Adam Brown 
 
 
Vitamin A metabolites and retinoids may slow the progression of breast cancer 
and elicit anti-neoplastic properties similar to those of omega-3 fatty acids. Studies using 
animal models show a decrease in the incidence, growth and metastisis of mammary 
tumors in the presence of specific fatty acids. This effect is also seen with use of 
retinoids, specifically all-trans retinoic acid (AtRA). Thus, fatty acids may also alter 
retinoid homeostasis in mammary carcinoma cells (MCF-7s). The potential for inter/co 
dependency among fatty acids and retinoids is considerable, and here it has been 
hypothesized that a decrease in cancer progression will occur in the presence of both 
compounds. MCF-7’s were seeded in a 48 well plate at 5,000 cells per well. After 24 hr, 
cells were treated with either 1 µM AtRA alone, fatty acids alone, or AtRA + fatty acids. 
Fatty acid treatments (Linoleic, and Linolenic) were administered at 2.5 uM 
concentrations. Each fatty acid treatment was also combined with 1 µM AtRA to 
determine if there is a synergistic effect on slowing cell growth. Both culture media and 
treatments were changed at 24 hour intervals over a 3 day trial. When compared to the 
controls, cells treated with 1 µM AtRA or 2.5 µM Linolenic acid both inhibited cell 
growth. Interestingly, when combined with Linolenic acid, AtRA treatment resulted in a 
significant (nearly 50%) additional growth inhibition when compared to treatment with 
AtRA alone. Our results suggest that AtRA and Linolenic acid have a inter/co 
dependency that significantly inhibits breast cancer cell growth in vitro by 73.4 % 
compared to control, and 49.7% compared to AtRA alone over 72 hours. We conclude 
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that AtRA and linolenic acid have a combined effect in breast cancer cell proliferation in-
vitro and their role in dietary prevention warrants further investigation. 
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Chapter 1 
INTRODUCTION 
All-trans retinoic acid (AtRA), the intracellular derivative of vitamin A, has been 
shown to slow the progression of human mammary carcinoma cells (MCF-7) in vitro 
(Danforth 2004, Cho et al. 2007).  Of perhaps equal importance is the role by which fatty 
acids contribute to tumor growth and stability. With both AtRA and intracellular fatty 
acid involvement with the nuclear hormone family of receptors, the possibility of 
synergism is substantial. Interestingly, altered nuclear receptor activity is known to 
increase carcinogenesis (Chamras et al. 2002). In either situation, both retinoids and fatty 
acids are directly involved with the cells ability to undergo apoptosis (Okamoto et al. 
2000) 
AtRA is responsible for cell growth, differentiation, and apoptosis (Liu et al. 
1996). This control is mediated via hormone receptors in the nucleus. MCF-7 cells have 
shown diminished hormone receptor efficiency which results in a decreased availability 
of AtRA. The result is a reduced amount of a ligand which promotes apoptosis via 
genetic transcription (Budhu 2002). The steroid-thyroid receptor super-family includes 
the retinoic acid receptor (RAR and RXR), which also includes receptors for estrogen and 
vitamin D (Tighe 2004). Recently, it has been shown that many carcinogenic cell types 
are missing retinoic acid receptors. Because retinoic acid seems to induce apoptosis, an 
accumulation of receptor deficient cells could be unresponsive to normal retinoic acid 
levels and therefore not undergo normal cellular death required for optimal health of the 
organism (Merino 2003). There are many pathways involved in this process and include 
those involving fatty acids. 
2 
 
Fatty acids have been under extreme scrutiny for their involvement in breast 
cancer incidence and progression. Both the protective effects of omega-3 fatty acids 
(linolenic), and the enhancing effects of omega-6 fatty acids (linoleic) have been 
demonstrated in the literature (Cohen et al. 1986, Chajès et al. 1995). While there is yet to 
be substantial evidence to directly link linoleic acid to breast cancer in vivo, animal 
studies, which have shown diminished breast cancer progression as a consequence of 
linolenic acid treatment (Reyes et al. 2004). Epidemiological studies also link fish oil, a 
classic source of omega-3, intake with lower breast cancer incidence (Rose 1999). 
Peroxisome proliferator-activated receptors (PpAR), members of the nuclear hormone 
signaling family are directly involved with breast cancer tumorogenesis (Thoennes et al. 
2000). Interestingly, Linolenic acid acts as an agonist to this receptor and therefore has 
yielded increased apoptosis in MCF-7 cells (Menendez et al. 2001). Using this acid 
presents a viable option to creating new and effective cancer treatments and establishing 
preventative lifestyle behavior choices. 
Separate investigations have confirmed the use of both AtRA and Linolenic acid 
to slow breast cancer proliferation in vitro by establishing a higher rate of apoptosis (Liu 
et al. 1996, Budhu 1996). Here, we combine the two treatments to investigate the 
synergism. We show that physiological treatments of both AtRA and linolenic acid 
further increase apoptosis when compared to each treatment alone. We believe the 
explanation is found on the surface of the nucleus where nuclear transporters are changed 
dramatically in a carcinogenic cell. The PpARy receptor and RXR receptor act together 
as a dimer and have a unique response element (PpARE) (Kim 2003). Up-regulation of 
this genetic activity seems to slow cancer proliferation, and is a viable explanation for our 
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observation of AtRA and linolenic acid as cancer treatments in vitro. Clearly, the 
functional significance of these findings will require further investigation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
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LITERATURE REVIEW 
2.1 Breast Cancer 
 Breast cancer is the second leading cause of death from cancer among American 
women (Reyes et al. 2004). It is estimated that 217,440 new cases of this cancer was 
diagnosed, and over 40,000 deaths occured in 2005 alone (Reyes et al. 2004). Age is one 
of the strongest risk factors in breast cancer. In women under the age of 30, breast cancer 
is very uncommon. The incidence rate begins to increase between ages 35 and 39 years 
and does not plateau until age 80 (Reyes et al. 2004). Breast cancer incidence is also 
influenced by race. In the United States, breast cancer risk is slightly higher in whites 
than in African Americans, although the incidence of early-onset cancers is higher in 
African Americans (Kuhajda 2000). Incidence rates are markedly lower in other racial 
and ethnic groups (Korde et al. 2004). The most common types of breast cancer occur in 
the lining of the ducts or in the lobules of the breast. Atypical ductal hyperplasia results 
in an overactive growth of cells lining the breast ducts, while lobular carcinoma results in 
uncontrolled growth of lobular cells. 
  On average, women have a 10% to 14% chance of having breast cancer by the time 
they reach 90 years of age (Reyes et al. 2004). Women at increased risk may have a 
strong family history of breast cancer, a known or suspected genetic predisposition for 
the disease, a history of radiation therapy, a previous problem of the breast, and a 5-year 
Gail model risk of 1.67% or greater (Murff et al. 2004). 
 There are two types of models used in breast cancer risk assessment--those that 
estimate the risk of breast cancer over time and those that estimate the risk of a mutation 
in one of the BRCA genes. These models are the Gail and Claus models, respectively. The 
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current version of the Gail model estimates the 5-year and lifetime risks of breast cancer 
by incorporating risk factors such as age, age of menarche, and age of 1st pregnancy. A 5-
year risk of 1.67% is considered elevated risk (Korde et al. 2004). The Gail model has 
proven to be very limited as it fails to incorporate paternal family history and ovarian 
cancer family history (Murff et al. 2004). In contrast, the Claus model is useful because it 
bases risk on family history of breast and ovarian cancers on both the maternal and 
paternal lineage. These two models compliment each other well, and together help 
women to define their risk of developing breast cancer. Defining risk can also prepare 
both physicians and patients for effective treatment. The only true shortcoming of these 
models is the continuing evidence that breast cancer is simply a mutation on the genome.  
 Breast cancer treatments vary depending on the advancement of the cancer, and the 
patient’s response to each treatment. The best opportunity to reduce mortality is through 
early detection (Maggiora et al. 2004). Generally, the location and size of the tumor in the 
breast and the extent of the disease in the armpit and the rest of the body will determine 
treatment options. Breast cancer progresses in stages. Stages 0-II are termed early stages, 
where the severity is a small tumor 1-2 inches in diameter with little or no lymph node 
invasion. Stage III is a progression towards the complete metastatic invasion known as 
type IV. The final stage is the most severe and advanced because of the extensive tissue 
invasion and malignancy (Maggiora et al. 2004). To develop a treatment plan to fit each 
patient's needs, the doctor also considers the woman's age and general health, as well as 
her feelings about the treatment options. The primary method of treatment is surgery. 
Few patients elect to bypass this option, as it is considered necessary to stop the cancer 
progression. The lumpectomy procedure removes a tumor from the breast, while a 
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mastectomy removes a portion of, or the entire breast. The need of the mastectomy is 
based on the progression of the cancer, and the literal “spread” of the cancer. This 
depends on the number of tumors in the area, as well as the condition of the local 
lymphnodes (Wiseman 2004). 
 The second step in treating cancer is radiation therapy, which uses x-rays and other 
radioactive materials to kill cancer cells. The radiation disrupts cell growth by destroying 
DNA and cell membranes (Serrano et al. 2004). This can be performed externally or 
internally depending on the growth of the cancer, and is effective when the cancer can be 
targeted in a specific area of the body.  
 The third step is chemotherapy, which is the use of chemical agents to either 
destroy dividing cells or stop their division. Chemotherapy can be localized, but in 
general is a systemic treatment. Gleevec, a pharmaceutical agent, inhibits cancer cell 
growth by inducing apoptosis. It binds to abnormal proteins in cancer cells, blocking 
uncontrolled cell growth. Because it binds only to these abnormal proteins, Gleevec does 
not show the high levels of toxicity exhibited by other chemotherapy drugs (Abou-Jawde 
et al. 2003). 
 The fourth and final treatment step is the use of hormone therapy. Hormone therapy 
can be used throughout the entire treatment process; however it is only applicable for 
certain types of breast cancer. In 1998, the Food and Drug Administration approved 
Nolvadex (tamoxifen citrate), which interferes with the activity of estrogen to reduce the 
incidence of breast cancer in women at high risk for developing the disease (Merino et al. 
2003). It is used as an additional type of therapy in conjunction with other steps in 
fighting the cancer (Abou-Jawde et al. 2003). The anti-proliferative effects of Tamoxifen 
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have been attributed to the inhibition of protein kinase C and its calmodulin binding 
(Abou-Jawde et al. 2003). The activity of these proteins is directly connected to the 
known breast cancer susceptibility genes.  
 
 
 
 
 
 
 
 
 
 
Figure 2.1.1. Image of Chromosome 17, and Chromosome 13, with location of BRCA1 
and BRCA2 respectively (National Library of Medicine, NCBI, www.son.wisc.edu). 
 
 
 Two breast cancer susceptibility genes have been identified. BRCA1 was found on 
chromosome 17 and BRCA2 was found on chromosome 13 (Serrano et al. 2003). When 
either gene has a mutation there is an increased risk of developing breast cancer and/or 
ovarian cancer. The genes were discovered in 1994, and until recently researchers were 
not able to identify their function (Abou-Jawde et al. 2003). A yeast study revealed that 
they repair radiation-induced “gaps” in double-stranded DNA. A mutant form of these 
genes causes these “gaps” to progress into tumor growth (Abou-Jawde et al. 2003). 
Human epidermal growth factor receptor 2 (HER2) along with the p53 gene have also 
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been shown to be causative factors when their mutations lead to breast cancer (Abou-
Jawde et al. 2003). 
 Lifestyle choices are a very important area of interest when determining possible 
sources of cancer development. Dietary influences have been heavily explored as of late, 
and have produced many promising links between diet and cancer. Vitamin A (retinoids) 
has been shown to play a major role in the progression of breast cancer cells in vitro 
(Merino et al. 2003). This important vitamin can change its role on the molecular level 
when not readily converted to its active form (retinoic acid) and leads to unnatural control 
over the human genome yielding cancerous growth. Scientists currently believe that the 
link between fatty acids and breast cancer is also substantial. Saturated fatty acids have 
been termed carcinogenic for some time, and omega 6 fatty acids seem to be following 
that trend and have been linked to breast cancer incidence (Thoennes et al. 1999).  
 On the contrary, antioxidant-rich foods protect normal cellular growth processes. 
Polyphenols, vitamin C, and Vitamin E have been toted as the great cancer preventors. 
While studies show these factors to be greatly protective against oxidative and free 
radical damage, there is little evidence to support these facts on the molecular and 
genomic level for breast cancer (Mezzetti 2001). While scientists may not argue against 
having a vegetable rich diet to help prevent cancer, the conclusive evidence for such has 
yet to be uncovered.  
 Diet is not the only lifestyle choice influencing cancer risk. Epidemiologic data 
regarding physical activity suggest a 20% to 30% reduction in the risk of breast cancer in 
women who are physically active compared with those who are inactive (Wiseman 
2004). In addition, moderate to heavy alcohol intake (more than 45 g of alcohol, or three 
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drinks, per day) has been shown to increase the risk of cancer, in a dose-response 
relationship (Wiseman 2004). High alcohol consumption causes the liver to be less 
effective at controlling estrogen levels in the body. This results in increased estrogen 
exposure to cells, and an increase in the chance of cancerous cell growth. 
 High levels of hormones, particularly estrogens, have been shown to be associated 
with increased breast cancer occurrences (McClelland 2004). Another theory claims that 
breast cancer progresses over time, and only becomes a clinical disease later in life 
(Wiseman 2004). The decisions women make regarding different hormone therapies 
influence breast cancer risk. These decisions include the use of oral contraceptives, 
excessive exercise, and hormone replacement therapy. The increased exposure of breast 
tissue to estrogen during these treatments has a direct link as a risk factor. The use of 
hormone replacement therapy for the difficulties of menopause has also been shown to 
increase cancer susceptibility from 5-40% (Wiseman 2004). Oral contraceptive use has 
been controversial about its potential increase in breast cancer risk. However, the most 
recent data suggests that oral contraceptive use is not associated with increased risk of 
breast cancer (Korde 2004).   
 
2.2 Retinoic Acid and Breast Cancer 
The vitamin A metabolite retinoic acid (RA) and its derivatives are effective 
chemotherapeutic agents in the treatment of a number of types of cancer, including 
tumors of lung, breast, head and neck, and blood (Sun et al 1997). The historical and 
most significant finding to date has been the use of retinoids to treat acute promyelocytic 
leukemia (APL) (Jimenez-Lara et al. 2004). Along with chemotherapy, the prognosis for 
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the disease has improved rapidly. In animal models, retinoids have antitumor activity in 
cancer xenografts and induced regression of mammary carcinoma (Lehmann et al. 1991). 
In vitro, RA and its derivatives inhibit proliferation of a variety of tumor types including 
lung, breast, leukemia, and rhabdomyosarcoma (Lehmann et al. 1991). Retinoids exert 
their function on tumor growth in three ways: increased cellular differentiation, decreased 
cell proliferation, and induction of apoptosis (Merino et al. 2004). Retinoids are known to 
inhibit hormone dependent, but not hormone independent mammary carcinoma cells (Liu 
et al. 1996). Thus, retinoids are currently being used as a treatment for many epithelial 
cancers (Liu et al. 1996).  
Retinoic acid receptors (RAR) and RA in cancer therapy was initiated in the 
1970’s when RA treatment was shown to disrupt anchorage-dependent growth in a few 
different cell lines (Lehmann et al. 1991). Recently, it has been shown that many 
carcinogenic cell types are missing retinoic acid receptors. Because retinoic acid seems to 
induce apoptosis, an accumulation of receptor deficient cells could be unresponsive to 
normal retinoic acid levels and therefore not undergo normal cellular death required for 
optimal health of the organism (Liu et al. 1996). In the nucleus, the RARs mediate the 
effects of RA on gene expression. The RARs are members of a large family of ligand-
dependent transcription factors that include steroid, thyroid hormone, and vitamin D 
receptors (Bischoff et al. 1998). Numerous synthetic retinoids with receptor selective 
activities have been characterized. RARs have functional domains for RA and DNA 
binding, dimerization with other factors, and transcriptional activation. The DNA binding 
domain contains two zinc finger motifs. RARs interact with cognate response elements in 
the promoters of many genes. RARs bind DNA as heterodimers with retinoid X receptors 
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(RXRs). RXRs bind 9-cis RA and possess homology to other members of the superfamily 
(Mangelsdorf et al. 1995) 
 
 
Figure 2.2.1. RXR binding partners 
 
RARs have 6 domains named A-F. Domains A and B appear to be ligand 
independent transcription domains. Domain C is the DNA-binding domain, and D is a 
things domain specific for nuclear translocation and/or co-repression. Domain E seems to 
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be for both dimerization and ligand binding. The F region is unknown to date (Sommer et 
al. 2002). When examining the role of RAR and its own genetic transcription, there 
appears to be a promoter problem in tumoregenic cells (Sun et al. 1997). There are three 
genes coding for RAR, but the problematic gene is RAR-beta. The gene has two 
promoters, one of which (P2) is highly down regulated. The transcription of this gene is 
controlled by a RARE, and thus RAR. It is a unique feedback mechanism which becomes 
disrupted in mammary carcinoma cells (Sommer et al. 2002). 
 Acyclo-retinoic acid was investigated for its possible role in activating the retinoic 
acid response element and slowing proliferation of immortal human mammary carcinoma 
cells (MCF-7) cells in culture. This retinoid is structurally and functionally similar to 
Lycopene (Leblanc et al. 1995). The result of the study showed a 100-fold decrease in 
RARE activity when compared to retinoic acid alone. Lycopene apparently does not 
show a direct affect on MCF-7 breast cancer cells, and does not act in place of retinoic 
acid (Ben-dor et al. 2002). MCF-7 cells treated with lycopene did not undergo apoptosis; 
however, they did show reduced activation of AP-1 transcription factor, IGF-1 receptor 
signaling, and cell cycle progression. These results indicate an inteference in cell cycle 
pathways by lycopene, which could be the reason for it’s prescribed affect of reducing 
cancer risk (Ben-dor et al. 2002). 
 
2.3 Fatty Acids and Breast Cancer 
In 1982 the National Academy of Sciences suggested that breast cancer was 
related to consumption of a high fat diet (Kushi et al. 2002). Studies now show that it is 
also the type of fat consumed, not just the amount of fat contributing to the rise in breast 
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cancer incidence. For example, Indian women have a high incidence of breast cancer in 
spite of a diet rich with fruits and vegetables (Kushi et al. 2002). In India, most foods are 
prepared with n-6 polyunsaturated rich vegetable oils (Kachhap et al. 1999). Case-control 
studies in Greece, Spain, and Italy have shown that consumption of olive oils 
(monounsaturated fat) reduce the incidence of breast cancer (Kushi et al. 2002). This 
protective effect may be due in part to its phenolic compounds that offer protection of 
lipids from oxidation (Gerber 1997). Another example of a specific fatty acid is 
Conjugated linoleic acid (CLA). This fatty acid is found in meat and dairy products. It 
can inhibit carcinogenic rat mammary tumor formation (Durgam 1997). The final lipid of 
interest is the omega-3 fatty acid. This fatty acid is considered anti-inflammatory, and has 
protective properties against breast cancer (Chajès et al. 1995). 
Although not all experts agree, women who consume foods rich in omega-3 fatty 
acids routinely and over long periods of time are less likely to develop breast cancer then 
those that consume them sparsely (Wayne et al. 2004). Breast cancer mortality also 
seems significantly less for those who consume large quantities of omega-3 fatty acids. 
This is particularly true among women who substitute fish for meat in their diet. The 
balance between omega-3 and omega-6 fatty acids suggests an important role in the 
development and growth of breast cancer (Simopoulos 2002). Further research is still 
needed to understand the affect that omega-3 fatty acids may have on the prevention or 
treatment of breast cancer. Researchers speculate that omega-3 fatty acids may be more 
effective in combination with other nutrients (vitamin E, vitamin C, beta-carotene) in the 
treatment and/or prevention of breast cancer (Rose et al. 1999). 
Studies on the effects of dietary fat on breast cancer have been carried out using 
several rodent experimental models. They consistently show that mice and rats are less 
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likely to develop mammary tumors when they are fed low-fat as compared to high-fat 
diets (Cohen et al. 1986). Experimental evidence shows that dietary fat exerts its effect 
most commonly during the promotion phase of developing mammary tumors. However, 
the type of fatty acid is paramount in relation to breast cancer. For example, a diet 
providing a high proportion of n-6 polyunsaturated fatty acids (PUFA) greatly enhances 
tumor promotion (Simopoulos 2002). In contrast, diets high in linolenic acid found in fish 
oil inhibited the progression of mammary carcinogenesis (Rose et al. 1999). Studies on 
the influence of diets rich in monosaturated fatty acids such as olive oil, are inconclusive 
but at this time there are several results which give them a protective antitumor effect. 
More recently, it has been described that conjugated linoleic acid has also inhibitory 
effects on breast cancer (Durgam 1997). 
The precise molecular mechanisms by which dietary fat might influence cancer 
development are potentially numerous as dietary fatty acids can modulate gene 
expression resulting in changes in metabolism, cell differentiation, and proliferation. 
Further, the cellular response to fat depends on the type of fatty acids, cell-specific 
metabolism and cell-specific transcription factors and nuclear receptors. The effects of 
dietary fat on tumor development may be indirect as a modulation of hormonal or growth 
factor mediated pathways. In addition, the oxidative stress due to generation of reactive 
oxygen species from fatty acids may contribute to the promotional effect of dietary fat by 
lipid peroxidation and damage of DNA and protein. Further, the metabolism of dietary 
fatty acids via the cyclooxygenase or lipoxygenase pathways may alter gene expression 
through the regulation of G proteins involved in signal transduction cascades that target 
the nuclear receptors. 
2.4 Fatty Acids 
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Dietary fats, more specifically, fatty acids have become increasingly scrutinized 
over the last few decades. At the center of this scrutiny are the omega 3 and omega 6 
fatty acids, with saturated and trans fatty acids following close behind. Omega 3 (GLA, 
DHA) fatty acids possess anti-inflammatory, antiarrhythmic, and antithrombotic 
properties. Omega 6 fatty acids (Linoleic) are proinflammatory and prothrombotic 
(Thoennes et al. 1999). Saturated fats and trans fats have been shown to increase LDLs, 
and subsequently have lead to an American population plagued by high cholesterol and 
heart disease (Kushi et al. 2002). Some scientists would argue that people simply eat a 
poor ratio of these different fats. Americans have a high ratio of omega-6 fatty acids to 
omega-3 fatty acids in their diets. Simopoulos suggests that humans evolved with a ratio 
close to one, and the distance from that ratio of the western diet is a link to increased 
levels of mortality and morbidity (2002). The deviation from the evolutionary ratio seems 
to be a historical indicator for fatalities resulting from cardiovascular disease and cancer 
(Simopoulos 2002).  
Fatty acids are an integral part of every physiological system in the human body. 
They are responsible for absorption of many essential nutrients such as vitamins A, D, 
and K. When examining fatty acids it is important to differentiate between dietary fatty 
acids and fatty acids actively involved in metabolic processes. Dietary fatty acids are 
typically defined by the food one eats. For example, mono-unsaturated fats originate from 
olives, saturated fats originate from animals, omega-3 fats originate from fish, and of 
course trans fats are a product of partial hydrogenation. Fats are commonly defined 
metabolically. For example, the omega-3 fatty acid alpha linolenic acid (ALA) is a 
precursor to eicosopentaenoic acid (EPA), which in turn is a precursor for 
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docosahexaenoic acid (DHA). Linoleic acid (LA), an omega-6 fatty acid,  is the 
metabolic precursor to arachidonic acid (AA) (Rose et al. 1999). These fats are known as 
essential fatty acids (EFA), as the body does not synthesize them. Essential fatty acids 
belong to the class of fatty acids called polyunsaturated fatty acids (PUFAs). They have 
many functions among which are, stimulate hair and skin growth, maintain bone health, 
regulate metabolism, and maintain the capability to reproduce (Kachhap et al. 2000).  
They serve in forming body structures, maintaining immune system function, protecting 
vision, creating cell membranes, and producing eicosanoids (Thoennes et al. 1999). 
Eicosanoids, which include prostaglandins, are regulators of temperature, immune 
response, blood clotting, blood pressure, and inflammatory response.  
 
2.4.1 Omega 3 Fatty Acids 
Omega 3 fatty acids have been directly linked to the health of a human being. The 
omega-3 fatty acids are effective in the treatment of cardiovascular disease, arthritic 
disorders, and diabetes mellitus (Rose et al. 1999). The dietary omega-3 fatty acids that 
may impact cancer include eicosapentaenoic acid (EPA) and docosahexanoic acid 
(DHA). These fats are found primarily in fatty fish such as salmon and tuna (Rose et al. 
1999).). Another rich source of omega-3 fatty acids is seaweed, and is the only true plant 
source of EPA and DHA. The other omega-3 fatty acid is ALA and is readily found in 
flaxseed and dark leafy green vegetables. The body can enzymatically convert ALA to 
EPA. All three fatty acids are paramount to human health (Simopoulos 2002). 
Approximately 1 g of EPA acid DHA consumed per day orally is recommended 
for cardio protection. Higher dosages of omega-3 fatty acids are required to reduce 
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elevated triglyceride levels (2 to 4 g per day) and to reduce the stiffness in the number of 
joints in patients with rheumatoid arthritis (at least 3 g per day)( Rose et al. 1999).). 
Small decreases in blood pressure can occur with higher dosages of omega 3 fatty acids 
(Rose et al. 1999).). 
 
2.4.2 Omega 6 Fatty Acids 
Omega 6 fatty acids are derived from a variety of sources. Most omega 6 fatty 
acids are consumed in the human diet, and are found in vegetable oils as linoleic acid. 
Linoleic acid is converted to gamma-linolenic acid (GLA), and then further broken down 
to arachidonic acid (AA). Arachidonic acid can also be consumed directly from meat. 
Gamma-linolenic acid can be part of a diet containing specific plant oils including: 
evening primrose oil (EPO), borage oil, and black currant seed oil (Kachhap et al. 2000).    
 Excess amounts of LA and AA are unhealthy because they can promote 
inflammation, which can potentially lead to heart disease and cancer (Reyes et al. 2004). 
In contrast, GLA seems to reduce inflammation (Cohen et al. 1986). When GLA is taken 
as a supplement, it is not converted to AA. Rather, it is converted to dihomogamma-
linolenic acid (DGLA). Dihomogamma-linolenic acid competes with AA and prevents 
the normal inflammatory effects that AA would have caused the body. Dihomogamma-
linolenic acid also becomes involved with prostaglandins, which reduce inflammation. 
Important dietary concerns are considered for this process to take place. Adequate 
amounts of magnesium, zinc, and vitamins B3, B6, and C help to promote the conversion 
of GLA to DGLA (Reyes et al. 2004).    
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2.4.3 Monounsaturated Fatty Acids 
 Monounsaturated fatty acids have functionally specific roles in the human body.  
These fatty acids are an important source of energy for the body, and are also important 
constituents of cell membranes. Monounsaturated fatty acids regulate hormone response, 
nutrient uptake, and waste removal. They are also very important as oils of the skin 
(Gerber 1997). 
 Monounsaturated fatty acids (MUFAs) have a single double carbon bond found 
with a cis configuration. These fatty acids cannot closely associate with neighboring fatty 
acids due to this double bond and consequently act as a liquid oil at room temperature. 
Monounsaturated fatty acids can be synthesized in the body, and are normally completed 
by a double bond insertion between the ninth and tenth carbons of a saturated fatty acid. 
This reaction creates either oleic acid or palmitoleic acid, depending on the original 
saturated fat. The common fat, oleic acid, is created using stearic acid. Palmitoleic acid is 
created from a palmitic acid chain. Together, these two fatty acids can be found in a 
variety of foods. Oleic acid is present in almost all animal fats and vegetable oils. It is the 
most common fatty acid in olive oil, canola oil, and sunflower oil. Palmitoleic acid is 
found in coconut and palm oils (Gerber 1997). 
 
 
2.4.4 Conjugated Linoleic Acid 
Conjugated Linoleic Acid (CLA) has been shown to be a very effective treatment 
in preventing the proliferation of breast cancer cells in vitro (Maggiora et al. 2004). 
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Conjugated Linoleic Acid is a mixture of positional and geometric isomers of linoleic 
acid. It is found in ruminant foods such as meat and dairy products (0.6 – 5.6 mg CLA/g 
fat), and has proven to be an effective inhibitor of carcinogenic rat mammary tumors 
(Durgam 1999). It is unique due to its presence in animal food sources, and its anticancer 
efficacy is expressed at concentrations close to human consumption levels.  
 CLA has been shown to increase metabolic rate, decrease body fat, increase lean 
muscle, lowers cholesterol and reduces insulin resistance. CLA is a slightly altered form 
of LA, an omega-6 fatty acid important to human health. Recently, it has been widely 
produced as a supplement which claims cancer prevention. It remains to be extensively 
tested and/or completely understood (Chujo et al. 2003). 
 
2.4.5 Trans Fatty Acids 
On November 12, 1999, the Food and Drug Administration announced that it 
would include the trans fatty acid content of foods on standard food labels. Metabolic 
studies reveal that trans fats have adverse effects on blood lipid levels increasing LDL 
cholesterol while decreasing HDL cholesterol. This combined effect on the ratio of LDL 
to HDL cholesterol is double that of saturated fatty acids (Mensink 2008). Trans  fats 
have also been associated with an increased risk of coronary heart disease in 
epidemiologic studies (Willett 2007). 
 Unsaturated fatty acids are naturally found in a cis configuration. Trans fatty acids 
have the hydrogen atoms on opposite sides. These trans double bonds can occur naturally 
in ruminants, and will show low levels in many meat and dairy products. Trans 
unsaturated fatty acids are produced artificially by introducing heat to liquid vegetable 
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oils in the presence of metal catalysts and hydrogen (Katan 2009).  
 
2.5 Vitamin A 
Vitamin A is a generic term for a large number of related compounds. The alcohol 
form is named retinol, while the aldehyde is termed retinal. These are commonly referred 
to as pre-formed vitamin A. Retinoic acid is formed in the body from retinal and is 
actively involved in molecular processes. These three compounds as well as others 
similar in form and function are collectively known as retinoids. Another group of 
compounds known as carotenoids have been termed provitamin A. Beta-carotene is found 
in this category, and is found in a variety of sources in the environment (Prakash et al. 
2000). 
Vitamin A is found naturally and occurs in many forms from a variety of both 
plant and animal sources. Retinol, the free form, is not found in foods. Carotenoids are 
found specifically in plants. Leafy green, and brightly colored are the most significant 
sources of carotenoids (Prakash et al. 2000). Retinyl palmitate is the major source of 
retinol found in animals. It is a storage form which acts as a precursor for retinol. In those 
foods where retinol activity comes mainly from provitamin A carotenoids, the carotenoid 
content and the retinol activity equivalents are presented (Thurnham et al. 2003). The 
USDA food composition database provides the content of several different carotenoids, 
including lycopene, lutein and zeaxanthin. 
Vitamin A exists as provitamin B carotene found in foods such as milk, eggs, and 
many fruits and vegetables. It is absorbed in the intestine and travels to the liver as a 
retinyl ester. It is stored in the liver, or its ester is cleaved and it travels through the body 
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bound to retinol binding protein (RBP). Retinoic acid is transported bound to albumin. 
Once retinol enters the cell it binds to cellular retinol binding protein (CRBP) and from 
there can be oxidized into retinal and retinoic acid by retinaldehyde dehydrogenase (Lei 
2003). It has been shown that genes induced by retinoic acid transcription factors control 
most of the targets involved in the metabolic activities of retinoids. It is a unique 
feedback system, which shows the dependency of the organism on these processes (Lei 
2003). 
Retinol from dietary sources (vitamin A) is metabolized intracellularly and results 
in its active versions: all-trans retinoic acid (tRA) and 9-cis retinoic acid (9-cis RA).  
Retinoid functions are exerted through their binding with their receptors. The receptors 
are termed retinoic acid receptors (RAR) and retinoic x receptors (RXR) (Ben-dor et al. 
2002). The difference between the two is RARs have a high affinity for all-trans-retinoic 
acid, while the RXRs tend to bind with cis forms of retinoic acid. The receptors act as a 
dimer, and then (bound to their ligand) are imported into the nucleus as transcription 
factors where they bind to the retinoic acid responsive element (RARE) (Ben-dor et al. 
2002). While RAR bound to trans-RA seems to have an antiproliferative effect on MCF-7 
cells in culture, RXR does not show any effect on cell growth. Cis-RA and RXR have not 
been shown to result in the same level of cancer suppression as RAR and trans-RA (Liu 
et al. 1996). 
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Figure 2.5.1 Retinol conversions (a) and binding sites (b) intracellularly 
 
Vitamin A deficiency among children in developing nations is the leading 
preventable cause of blindness (Semba et al. 2004). The most common diseases 
associated directly with vitamin A deficiency is of the eye. Night blindness from 
impaired 11- cis retinal production is common (Semba et al. 2004). Also a condition of 
the conjunctiva called Bitot’s spots can be observed during a deficiency (Semba et al. 
2004). The most severe form of vitamin A deficiency in the eyes is known as 
xeropthalmia. This condition leads to dry eyes, corneal ulcers, scarring, and eventually 
total blindness (Semba et al. 2004). Vitamin A deficiency is also considered an acquired 
immunodeficiency disease as described by Semba. Inadequate vitamin A intake has also 
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been shown to lead to increased incidence of infectious disease. Interestingly, vitamin A 
supplementation in developing countries decreases deaths in children from diarrhea and 
measles (Thurnham et al. 2003). 
The RDA  for vitamin A was revised by the Food and Nutrition Board (FNB) of 
the Institute of Medicine in 2001. Vitamin A has an RDA of 900mcg/day for men and 
700mcg/day for women. The latest RDA is based on the amount needed to ensure an 
adequate store of vitamin A in the body. This store is a sufficient amount to support 
normal vision, immune function, maturation, growth, and gene expression (Semba et al. 
2004). 
 Vitamin A is an integral part of the signal transduction required for vision. As light 
passes through the lens of the eye, it is received by the retina located at the rear of the 
eye. The light is then converted to a signal, which the brain translates into vision. At the 
epithelial surface of the retina, retinol is  esterified to form a retinyl ester. These esters are 
then isomerized following hydrolysis and become 11-cis retinol. Following oxidation this 
compound becomes11-cis retinal. The importance of 11-cis retinal is its ability to bind to 
opsin and form rhodopsin. Rhodopsin is found on rod cells of the eye, which are 
important in night vision. 11-cis retinal isomerizes to all-trans retinal, which results in the 
signal cascade responsible for vision.  
 Vitamin A is necessary for the normal and healthy activities of the human immune 
system. Better known as retinol, vitamin A and its metabolites are required to maintain 
the correct function of the mucosal cells (epithelial cells) found in the urinary, digestive, 
and reproductive tracts. Retinol and retinoic acid (RA) have an integral role in the 
development and differentiation of lymphocytes, and AtRA is required by T-lymphocytes 
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for proper regulation of the immune system.  
 Both vitamin A excess and deficiency are known  to cause birth defects. Retinol 
and retinoic acid (RA) are essential for embryonic development (Christian 2003). During 
fetal development, RA  functions in limb development and formation of the heart, eyes, 
and ears (Pavia 1999). Additionally, RA has been found to regulate expression of the 
gene for growth hormone (Christian 2003) 
Red blood cells, like all blood cells, are derived from precursor cells called stem 
cells. These stem cells are dependent on retinoids for normal differentiation  into red 
blood cells. Additionally, vitamin A appears to facilitate the mobilization of iron from 
storage sites to the developing red blood cell for  incorporation into hemoglobin, the  
oxygen carrier in red blood cells (Christian 2003). 
 Delivery of RA to its receptor within the cell has been a topic of interest recently, 
and it has yet to be fully understood. The current theory on RA delivery is a combination 
of passive diffusion and the action of a carrier protein. Cellular retinoic acid binding 
protein II (CRABPII) has been uncovered as that carrier protein. Upon binding to its 
ligand (RA) it undergoes a massive conformational change in the cytosol near the 
nucleus. The change causes a rapid recruitment into the nucleus where RA is delivered to 
its receptor RAR or RXR. The collision-mediated process leaves the binding protein 
empty and is then immediately exported from the nucleus back to the cytosol where it 
awaits another ligand. Recent research has concluded that the CRABPII is a necessary 
and exciting pathway by which retinoic acid induces growth arrest in mammary 
carcinoma cells (Budhu et al. 2002). Over expression of CRABPII in MCF-7 cells 
showed a significant decrease in cell proliferation, while silencing the protein allowed the 
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cells to proliferate as if there was no RA in the treatment. 
2.6 Nuclear Hormone Receptors 
 Nuclear hormone receptors may be responsible for the combines effect of Vitamin 
A and Fatty Acid on carcinogenesis. More specifically, the peroxisome proliferator-
activated receptors (PPARs) are the hypothesized to play a role in the decreased cell 
proliferation. (Moller et al. 2003). The PPARs are ligand-activated transcription factors 
of the nuclear hormone receptor superfamily. They share a high degree of structural 
homology with all members of the superfamily, particularly in the DNA-binding domain 
and ligand- and cofactor-binding domain. Many cellular and systemic roles have been 
attributed to these receptors, reaching far beyond the stimulation of peroxisome 
proliferation in rodents after which they were initially named. Peroxisome proliferator-
activated receptors exhibit broad, isotype-specific tissue expression patterns. PPAR  is 
expressed at high levels in organs with significant catabolism of fatty acids. PPAR /  has 
the broadest expression pattern, and the levels of expression in certain tissues depend on 
the extent of cell proliferation and differentiation. PPAR  is expressed as two isoforms, 
of which PPAR 2 is found at high levels in the adipose tissues, whereas PPAR 1 has a 
broader expression pattern.  
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Figure 2.6.1: PPAR alpha and gamma pathways. 
 
 Transcriptional regulation by PPARs requires heterodimerization with the retinoid 
X receptor (RXR)( Vu-Dac et al. 1998). When activated by a ligand, the dimer modulates 
transcription via binding to a specific DNA sequence element called a peroxisome 
proliferator response element (PPRE) in the promoter region of target genes (Kersten et 
al., 1999). A wide variety of natural or synthetic compounds have been identified as 
PPAR ligands. Among the synthetic ligands, the lipid-lowering drugs, fibrates, and the 
insulin sensitizers, thiazolidinediones, are PPAR  and PPAR  agonists, respectively, 
which underscores the important role of PPARs as therapeutic anti-cancer targets (Staels 
et al., 1998). Transcriptional control by PPAR/RXR heterodimers also requires 
interaction with coregulator complexes (Kersten et al., 2001). Thus, selective action of 
PPARs in vivo results from the interplay at a given time point between expression levels 
of each of the three PPAR and RXR isotypes, affinity for a specific promoter PPRE, and 
ligand and cofactor availabilities. 
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 Consistent with its distribution in tissues with high catabolic rates of fatty acids and 
high peroxisomal activity, the major role of PPAR  is the regulation of energy 
homeostasis (Lefebvre et al. 2006). In the liver especially, PPAR  activates fatty acid 
catabolism, stimulates gluconeogenesis and ketone body synthesis, and is involved in the 
control of lipoprotein assembly (Staels et al. 1995). PPAR  also stimulates heme 
synthesis and cholesterol catabolism (Staels et al. 1995). Furthermore, it attenuates 
inflammatory responses and participates in the control of amino acid metabolism and urea 
synthesis (Devchand et al. 1999). Increased fatty acid oxidation by activated PPAR  
lowers circulating triglyceride levels, liver and muscle steatosis, and reduces adiposity, 
which improves insulin sensitivity (Guerre-Millo et al. 2000; Chou et al. 2002). Not 
surprisingly, fibrate drugs such as gemfibrozil, clofibrate, and fenofibrate that are widely 
used to treat hypertriglyceridemia are activators of PPAR . In addition, PPAR  agonists 
have demonstrated significant anti-inflammatory activities that seem to play a role in their 
protective actions within the cardiovascular system (Berger et al. 2005). 
 
2.7 Nutrient Delivery Systems 
 The delivery of AtRA has not been easily performed to date. The goal of 
establishing therapeutic levels of AtRA in tissue has also met some barriers. These 
barriers include issues of compound stability, and also tissue safety.  
While beneficial as an anti-cancer agent, the use of AtRA is not without 
complications. AtRA is a water insoluble, toxic agent with limited bioavailability 
(Freemantle et al. 2003). Pharmacological levels can cause retinoic acid syndrome and 
neurotoxicity, particularly in children (Takitani et al. 2006). In addition, drug resistance 
has been reported in cases of sustained ATRA treatment requiring the use of additional 
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cytotoxic chemotherapy (Freemantle et al. 2003). Although liposomal formulations were 
developed a number of years ago in an effort to address these issues, they have not 
progressed past the clinical trial stage (Freemantle et al. 2003). Despite this, the potential 
benefits of associating ATRA with a lipid-based carrier are many. Not only do lipid-drug 
formulations address solubility issues, they also decrease toxicity and potentially avoid 
triggering ATRA resistance, thereby minimizing the need for additional chemotherapy 
(Freemantle et al. 2003). 
 In conjunction with this study, our research team was involved in exploring 
possible applications of the above named Liposomes. Liposomal delivery offers many 
specific stability advantages of AtRA, and we were able to produce results in vitro 
supporting the possibility of further usage. The application model stemmed from using 
dairy based fatty acids to produce liposomes that delivered AtRA. Appendix D has the 
full results. Liposome use is a viable option for future delivery of AtRA and could be 
engineered with specific fatty acids as well. The search for a viable delivery option from 
liposomes is currently underway, and should yield realistic applications in the future to 
treat carcinomas. 
 
 
 
 
 
 
 
 
Chapter 3.0 
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MATERIALS AND METHODS 
 
3.1 Materials 
 
MCF-7 cells were obtained from the American Type Institute. AtRA was obtained 
from Sigma Aldrich (St. Louis MO). Fatty Acids and other chemicals were obtained from 
Fisher Scientific (Pittsburgh, PA). 
 
3.2 Cell Experiments 
 
MCF-7 cells were cultured at 37 °C, 5% CO2, in Dulbecco’s Modified Eagle 
Media (DMEM) containing 10% fetal bovine serum (FBS) and 1% antibiotic. FBS and 
the antibiotic (50:50, penicillin and streptomycin) added to the media, sterile filtered 
using a bottle top vacuum filter. 75cm^2 cell culture flasks were carefully monitored for 
confluence and were passed upon a 75% confluency. Cells were grown consistently in 20 
ml of media until confluent. MCF-7 cells did not require a media change to ensure 
confluency. The cells were considered “stock” cells which were transferred to growth 
plates for growth assays. 
 
3.3 Cell Counting 
Cells collected via trypsin in a 15 ml Falcon tube. The tube spun at 1800 RPM for 
5 minutes in a centrifuge to collect pellet. The cells were resuspended by light vortexing 
in 1 ml of fresh media. Sample (5 ul) of cells was counted on a hemacytometer (Figure 
3.1) to determine amount of cells in the 1 ml. 48 well plates seeded for cell proliferation 
assays, and each well contained 5000 cells as determined by a hemacytometer. Cells 
adhered for 24 hours before treatment.  
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3.4 Cell Treatments 
AtRA treatments began with a growth curve. Cells seeded in 48 well growth 
plates for 24 hours until confluent. Media removed, new media (void of FBS) containing 
treatments added. Stepwise increases in AtRA (in DMSO) concentration (.5 – 10 uM) 
were used, and cells analyzed after both 24 and 48-hour growth periods. 1 uM AtRA 
chosen to pair with fatty acid treatments. AtRA extinction treatments also examined at 
time zero, vs daily treatments over 72 hours.  
Fatty Acids (Linolenic, Linoleic, and Palmitic Acid) were used to treat the MCF-7 
cells over 24 and 48 hours. Later, 1 uM of AtRA was combined with 2.5 uM of each fatty 
acid. Growth carefully monitored over 72 hours with identical wells receiving either a 
single treatment at time zero, or receiving multiple treatments (1 every 24 hours). DMSO 
was controlled at 1% by volume. Each designated time period ended with media removal 
from each plate and placed in a – 20 degree C freezer for later analysis. 
 
 
 
 
 
Figure 3.1: View of hemacytometer grid (10x) and cells. Cells are counted in squares and 
determine the amount of cells in solution following calculation.  
 
3.5 Cell proliferation assay 
Cell proliferation measured by fluorescence using the Cyquant Cell Proliferation 
Assay Kit (Invitrogen CO. Carlsbad, CA). Each plate removed from freezer and thawed. 
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Nano-pure water (19 ml), lysis buffer (1 ml), and a florescent dye (50 ul) combined and 
added to each well in 200 uL aliquots. 30 minutes of incubation was required before the 
first reading and emission was stable for up to 60 minutes. 
 
3.6 Cell proliferation quantification 
A Typhoon Variable Mode Imager (General Electric Health Care) read the 
florescent stained cellular nucleic acids through a flourecein filter at 520 nm following a 
green laser excitation of the dye. Following the scan, the resulting image was 
manipulated and evaluated by the Imagequant TL software (Amersham Biosciences). 
Each well evaluated by color absorption then measured against control wells to give cell 
proliferation comparisons.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
 
RESULTS 
 
MCF-7 cell growth was limited by media containing AtRA. A growth curve 
analysis of MCF-7 cells in the presence of AtRA in varying concentrations was produced 
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to investigate its efficacy in decreasing cell proliferation.. Figure 4.1 shows the decrease 
in growth with each concentration as compared to media not supplemented with AtRA 
(control). 5uM AtRA concentration showed the largest decrease, the 1 uM concentration 
was chosen for further analysis. 1 uM decreased cell growth by 32.9% after 24 hours.  
 
 
 
 
 
 
 
 
 
Figure 4.1: Molecular Probes Cyquant Kit: 5000 cells were seeded per well and allowed 
to adhere overnight before treatments were given 24 hours later in serum free media. 
Proliferation was significantly altered with the use of ATRA. Columns C-F are 0.5uM – 
5.0uM AtRA in media respectively. (Images produced on a Typhoon Scanner, and 
manipulated with Imagequant software. (Image is of actual size) 
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Figure 4.2: Cell Proliferation Assay. Standard curve for cell growth under varying 
amounts of AtRA delivered in vitro. Ideal treatment was found to be 1 uM which was not 
greater than 50% cell growth reduction. (Numbers taken from Figure 1 to produce graph) 
 
 
Linolenic acid decreased MCF-7 cell proliferation in vitro. Linolenic acid 
delivered to MCF-7 cells via media over 72 hours decreased cell growth by 26.5%. 
Linoleic acid was used as a control to investigate fatty acids delivered in media. Linoleic 
did show a slight decrease in cell proliferation (10.1%), it was not consistent and was not 
considered significant.  
AtRA combined with Linolenic acid decreased MCF-7 cell proliferation greater 
than AtRA alone. Over 72 hours of refeeding treatments, 1 uM AtRA combined with 2.5 
uM Linolenic acid decreased cell proliferation by 73.4%. This was 49.7% less then AtRA 
alone, and 87.4% less than Linolenic acid alone. Figure 4.3 shows the percent growth of 
the control.  
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Figure 4.3: Cell Proliferation Assay: Data presented as percent of control. AtRA (1uM) 
along with AtRA + Linolenic acid produced significant growth differences over 72 hours. 
The combined affect was 49.7% greater then AtRA alone, and was significantly different. 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Molecular Probes Cyquant Kit: 5000 cells were seeded per well and allowed 
to adhere overnight before treatments were given 24 hours later in serum free media. 
Proliferation was significantly altered with the use of ATRA (1uM) and the combination 
of ATRA (1uM) with Linolenic Acid (2.5uM). Treatments were only affective with daily 
dosage as opposed to a single dosage on day 1. Columns C and F illustrate this 
difference. (Images produced on a Typhoon Scanner, and manipulated with Imagequant 
software. (Image is of actual size) 
4.1 AtRA and Linolenic Acid Combined Treatment Results 
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The combined affect of treatments was only seen after 72 hours of re-feeding, and 
cells given only 1 treatment on day 1 did not show the same results.  Figure 4.5 shows the 
relationship of single treatments vs. re-feeding daily treatments. 
 
Figure 4.5: Series 1 is cell proliferation following single treatment at time zero, vs series 
2 which is treatments every 24 hours.  
 
4.2 Statistical Analysis 
 Statistical significance (p<.05) was found when comparing AtRA+ linolenic acid, 
and linoleic acid treatments with an ANOVA. Daily AtRA feeding was statistically 
different (p<.05) from all of the other treatments accept AtRA combined with Linolenic 
Acid, and the Linolenic acid treatment alone. AtRA combined with Linoleic acid was 
significantly different (p<.05) from AtRA + linolenic Acid, and linolenic acid alone. 
Daily feedings were all statistically different (p<.05) from single feedings (at time zero) 
except for single AtRA feedings on day 1.  
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DISCUSSION 
All-trans retinoic acid has historically been evaluated and applied in 
chemoprevention of epithelial cancers. Linolenic acid has also been explored for possible 
application in chemoprevention. Here, we have explored the synergism of these two 
compounds through an in-vitro application in a specific cell line. We have also 
hypothesized the connection with these compounds to be found on the nuclear level in the 
form of transcription factor specific receptors: Perxisome-proliferator activated receptor 
gamma (PpARy), and Retinoic Acid receptor (RXR). MCF-7 cells are an appropriate 
choice when exploring RXR and PPAR do to their previous use in these applications. 
Other epithelial cell lines do not produce the same quantity of receptors and have not 
shown the same promising results. Unique expression patterns of PPARγ relative to RXR 
in certain cell lines led us to hypothesize that applying a known ligand for each receptor 
would significantly affect the progression of MCF-7 cell growth in vitro. Our hypothesis 
was supported by current research where up-regulation of the PPARE was noted with 
increased ligand activity of RXR (Nicol et al. 2004). 
A growing body of evidence indicates PPARγ is involved in both breast cancer 
development and progression. PPARγ(+/−) mice had almost three-fold increased 
incidence of mammary adenocarcinomas and decreased survival rate when compared to 
PPARγ(+/+) litermates (Nicol et al. 2004). Several reports have demonstrated that 
treating animals with PPARγ ligands prior to chemical induction of mammary tumors is 
protective against tumor development (Nicol et al. 2004). It appears that expression and 
transactivation of PPARγ is protective against breast tumor formation particularly when 
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activated by PPARγ ligands. Our data demonstrates that a particular ligand (Linolenic 
Acid) seems effective at transactivating PPARγ in normal mammary epithelia. 
Once a breast tumor has formed, PPARγ appears to have multiple effects. One 
study observed that distinct PPARγ ligands induce apoptosis (Nicol et al. 2004). 
Conversely, a recent report by Saez et al. (2004) found that when mice expressing a 
constitutively active form of PPARγ in the mammary gland were crossed with mice 
prone to mammary gland cancer, bigenic animals develop tumors that express higher 
levels of markers of malignancy. The authors conclude that once an initiating event takes 
place, increased PPARγ signaling serves as a tumor promoter in the mammary gland of 
these experimental animals. Collectively, these data suggest that the physiological 
consequence of PPARγ activation is dependent on many factors including the stage of 
development of the specific breast cancer cell.  
Our demonstration that an individual PPARγ ligand (Linolenic Acid) showed 
promising results follows the trend previously demonstrated in literature. We also 
demonstrated the use of a RXR ligand to slow the progression of MCF-7 cell growth in 
vitro. Interestingly, further decrease in progression was observed with the co-treatment of 
both ligands. The heterodimeric relationship of RXR and PPARγ has been shown to have 
its own response element PPARE which was shown to be up-regulated by ligands of 
either receptor independent of eachother. We have shown here that there is also promise 
of increased transcription through increased availability of both ligands.  
It can be concluded that individual breast cancer cell types are likely to respond to 
PPARγ ligands and RXR ligands in unique physiological ways and our data suggests that, 
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in part, variant cellular responses are the result of selective PPARγ transactivation. Our 
data demonstrates that individual PPARγ ligands combined with indivisual RXR ligands 
can selectively activate response element activity within a single cancer cell type. These 
data suggest that the effectiveness of PPARγ and RXR as a target for chemotherapeutic 
treatment will greatly depend on the cell that is treated which opens the possibility of 
utilizing PPARγ and RXR for targeted gene therapy. 
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Appendix A 
 
Cyquant Cell Proliferation Protocol 
 
1. On day of experiment, decide number of wells to be assayed. This will depend on 
number of treatments and number of plates. (For example, look to image below.) 
2. Obtain a plastic (preferably opaque) bottle, and aluminum foil.  
3. Dilute the stock 20x Lysis Buffer Solution to 1X, so add 1ml of buffer to 19ml of 
Nuclease free DI water. (note this is enough for 100 assays at 200ul each) 
4. Next make a 400 fold dilution with the Green Dye solution by adding 50ul of dye 
to the 1x lysis buffer. Cover with foil. Now we are ready. 
5. Use this solution within 2 hours of creation, and keep covered with foil for light 
protection. 
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Cell culture prior to day of assay 
 
6. Obtain a 96 well, or 48 well plate. 
7. Seed the wells with 5000 cells per well as obtained from a hemacytometer count. 
(Hemacytometer protocol is available and separate) 
8. Grow the cells with treatments (as described later) for specified durations. 
9. Blot the media from the wells, and freeze immediately at –70C for each time 
period. 
 
Day of assay protocol 
10. On day of assay, obtain plate from freezer and let thaw, then add 200ul of the 
working solution to each well to be assayed. 
11. Let mix and incubate for 5min, and cover the plate with foil to protect from light. 
12. Then use microplate reader to measure fluorescence with settings at 480nm 
excitation and 520nm emission maxima. 
 
Standard Curve Creation 
1. Obtain 96 or 48 well plate.  
2. Use hemacytometer to count cells from a confluent flask. 
3. Seed wells with 500, 1000, 2000, 5000, and 10000 cells per well 
4. Let cells adhere and incubate for 24 hours, then freeze. 
5. Run assay as described above, and pray for a linear relationship. 
6. Plate will be seeded as shown below. 
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Appendix B 
 
Hemacytometer Protocol 
 
Obtain 1 flask/plate of cells, and aspirate off media. Add 5 cc of Trypsin and place in 
incubator for 7-10 minutes. 
 
Add 15 cc of new media to trypsinized cells in flask, and mix via pipette. 
 
Aliquot 10 cc of cells + media into a new 15 cc conical tube, and repeat for other 10 cc 
left in flask. 
 
Take 2 15 cc conical tubes containing 10 cc of cells + media and place in centrifuge 
directly across from eachother for balance. Set to spin at 1800 rpm for 5 minutes. Set 
acceleration at setting 2, and deceleration at setting 9 at 18 degrees Celsius. (This is for 
Eppendorf centrifuge) 
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Take 15 cc tubes with visible cell pellets back to sterile environment to aspirate off 
media, and re-suspend cell pellet in 1 cc of new media. (Do this using a transfer pipette) 
 
With new transfer pipette, take small sample of cells plus media and slowly release onto 
hemacytometer. (The slide should have a coverslip on at this point, and is designed to 
disperse evenly due to small “channel” in glass) 
 
Place on upright (not inverted) microscope and view on the 5X objective lens to see cells. 
Optimal viewing found on 10 x objective lens. 
 
To count cells, first find center square with a 5x5 square profile. Count each corner 
square, and pick one more square in middle. (Note, this tactic only works if cells appear 
to be evenly distributed across slide… which they should!) Later the number is multiplied 
by 5 to account for other squares. 
 
Number will most likely be between 50-150. Then use the following equation: 
 
(cell # counted) x 5 x 10^4 x 1ml = # of cells in suspension 
 
Ex: 57 cells x 5 x 10^4 x 1ml = 2.85 x 10^6 
 
Next, decide how much to aliquot for each well on a 96 well plate.  
 
Ex: let’s assume we want 5,000 cells per well. 
 
.05 x 10^6 / 2,85 x 10^6 = .018ml or…. 18ul per well. 
 
Max well volume should not exceed a ceiling, Of 270 ul. Therefore, the media warmed 
before adding cells must be less than 252 ul in this case for each well. 
Appendix C 
 
Complete Experiment Results 
 
 The experiment concluded much more data then reported in the results section of 
Chapter 4. The results below are day to day results that were used for final analysis. As 
reported earlier, the results are described by either a single treatment on day one, or daily 
treatments over 72 hours. Each treatment is indicated as well. 
 
 
Day 1 
treatment 
Daily 
Treatment 
Cell Growth Treatment: Blank   
Day 1 18963751.5 18963751.5 
Day 2 21281242.5 21281242.5 
Day 3 27134548 27134548 
 
 
 
 
50 
 
 
 
 
 
 
 
Cell Growth (DMSO Control)   
Day 1 19276753.8 19276753.8 
Day 2 20773928.3 21777477.7 
Day 3 30964674.7 29658439.4 
 
  
 
 
Cell Growth (ATRA 1uM)   
Day 1 16084480 16084480 
Day 2 19283732.7 15140571 
Day 3 26206974.6 9057623.09 
 
 
  
 
Cell Growth (Linolenic 2.5 uM)   
Day 1 18397367.7 18397367.7 
Day 2 19290527 17852295.3 
Day 3 25327786.1 19938678.6 
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Cell Growth (Linoleic 2.5 uM)   
Day 1 19306580.7 19306580.7 
Day 2 21089190.7 20329843.7 
Day 3 26684736 24402016.1 
 
 
 
Cell Growth (ATRA 1 uM + Linolenic 2.5 uM)  
Day 1 13996046.2 13996046.2 
Day 2 19264504.3 12188983 
Day 3 23443646.3 4499775.95 
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Appendix D 
 
Liposome Delivery System Results 
 
 The research conducted here was in calloboration with the Dairy Products 
Technology Center at Cal Poly, San Luis Obispo during 2006-2007. Callaborators 
included Dr. Susan Hawk, Dr. Rafeal Jimenez, David Brown, and Jessica Yee. Other 
technicians included in the study were Selena Tinga, and Diana Rios. 
 The study yielded promising results, and would be an excellent starting point for 
future research. The project used a SuperCritical Fluid Extraction method to isolate milk 
lipids. These lipids were then manipulated through High Pressure Homogenization to 
creat Liposomes. The liposomes were also created with All-trans retinoic Acid as a 
nutrient to be delivered in vitro. Results were as follows: 
 
By Treatment   
   
Treatment Cell Growth (24hrs)             CONTROL                         
Imidazole 21981333.5 21281242.5 
Ethanol 20781992.5 21281242.5 
2.5 uM ATRA 15140571 21281242.5 
SE (SFE emulsiflex) 19701002.5 21281242.5 
SAE (SFE+ATRA+emulsiflex) 14740598 21281242.5 
SS (SFE sonicated) 20822992.5 21281242.5 
SAS (SFE+ATRA+sonicated) 14999579 21281242.5 
BE (buttermilk powder + emulsiflex) 20788888.5 21281242.5 
BAE (Buttermilk powder + ATRA + 
emulsiflex) 21001982.5 21281242.5 
BS (Buttermilk powder + sonicated) 19997654.5 21281242.5 
BAS (Buttermilk powder + ATRA 
+sonicated) 17140987 21281242.5 
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Control 21281242.5 21281242.5 
   
   
By method   
   
Control 21281242.5 21281242.5 
Imidazole 21981333.5 21281242.5 
Ethanol 20781992.5 21281242.5 
2.5 uM ATRA 15140571 21281242.5 
SAE (SFE+ATRA+emulsiflex) 14740598 21281242.5 
SAS (SFE+ATRA+sonicated) 14999579 21281242.5 
BAE (Buttermilk powder + ATRA + 
emulsiflex) 21001982.5 21281242.5 
BAS (Buttermilk powder + ATRA 
+sonicated) 17140987 21281242.5 
SE (SFE emulsiflex) 19701002.5 21281242.5 
SS (SFE sonicated) 20822992.5 21281242.5 
BE (buttermilk powder + emulsiflex) 20788888.5 21281242.5 
BS (Buttermilk powder + sonicated) 19997654.5 21281242.5 
 
 
54 
 
 
 
Appendix E 
 
Minitab Output 
 
General Linear Model: Count versus Treatment, Application  
 
Factor       Type   Levels  Values 
Treatment    fixed       7  Atra, Atra + Leic, ATRa +Lenic, control, dmso 
                            control, Linoleic, Linolenic 
Application  fixed       2  Daily, Single 
 
 
Analysis of Variance for Count, using Adjusted SS for Tests 
 
Source                 DF       Seq SS       Adj SS       Adj MS       F      P 
Treatment               6  1.12085E+15  1.12085E+15  1.86808E+14   30.92  0.000 
Application             1  8.82998E+14  8.82998E+14  8.82998E+14  146.16  0.000 
Treatment*Application   6  4.85275E+14  4.85275E+14  8.08792E+13   13.39  0.000 
Error                  28  1.69160E+14  1.69160E+14  6.04142E+12 
Total                  41  2.65828E+15 
 
 
S = 2457931   R-Sq = 93.64%   R-Sq(adj) = 90.68% 
 
Tukey 95.0% Simultaneous Confidence Intervals 
Response Variable Count 
All Pairwise Comparisons among Levels of Treatment*Application 
Treatment = Atra 
Application = Daily  subtracted from: 
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Treatment     Application      Lower    Center     Upper 
Atra          Single         9798481  17149352  24500222 
Atra + Leic   Daily         10675594  18026465  25377335 
Atra + Leic   Single        10306840  17657711  25008582 
ATRa +Lenic   Daily        -11908718  -4557847   2793024 
ATRa +Lenic   Single         7035153  14386023  21736894 
control       Daily          8981153  16332024  23682895 
control       Single        12470955  19821826  27172696 
dmso control  Daily          9249946  16600816  23951687 
dmso control  Single        14556181  21907052  29257922 
Linoleic      Daily          3993522  11344393  18695264 
Linoleic      Single        10276242  17627113  24977984 
Linolenic     Daily         -4469815   2881056  10231926 
Linolenic     Single         8919292  16270163  23621034 
 
Treatment     Application    -----+---------+---------+---------+- 
Atra          Single                             (---*--) 
Atra + Leic   Daily                              (---*---) 
Atra + Leic   Single                             (---*---) 
ATRa +Lenic   Daily                   (---*--) 
ATRa +Lenic   Single                            (--*---) 
control       Daily                             (---*---) 
control       Single                              (---*---) 
dmso control  Daily                              (--*---) 
dmso control  Single                               (---*---) 
Linoleic      Daily                           (---*--) 
Linoleic      Single                             (---*--) 
Linolenic     Daily                       (--*---) 
Linolenic     Single                            (---*---) 
                             -----+---------+---------+---------+- 
                           -2.0E+07         0  20000000  40000000 
 
 
Treatment = Atra 
Application = Single  subtracted from: 
 
Treatment     Application      Lower     Center      Upper 
Atra + Leic   Daily         -6473758     877113    8227984 
Atra + Leic   Single        -6842511     508359    7859230 
ATRa +Lenic   Daily        -29058069  -21707199  -14356328 
ATRa +Lenic   Single       -10114199   -2763328    4587542 
control       Daily         -8168198    -817327    6533543 
control       Single        -4678397    2672474   10023345 
dmso control  Daily         -7899406    -548535    6802335 
dmso control  Single        -2593171    4757700   12108571 
Linoleic      Daily        -13155829   -5804959    1545912 
Linoleic      Single        -6873109     477761    7828632 
Linolenic     Daily        -21619167  -14268296   -6917425 
Linolenic     Single        -8230059    -879189    6471682 
 
Treatment     Application    -----+---------+---------+---------+- 
Atra + Leic   Daily                      (--*---) 
Atra + Leic   Single                     (--*---) 
ATRa +Lenic   Daily          (---*---) 
ATRa +Lenic   Single                   (---*--) 
control       Daily                     (---*--) 
control       Single                      (--*---) 
dmso control  Daily                     (---*--) 
dmso control  Single                       (--*---) 
Linoleic      Daily                  (---*---) 
Linoleic      Single                     (--*---) 
Linolenic     Daily              (---*---) 
Linolenic     Single                    (---*--) 
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                             -----+---------+---------+---------+- 
                           -2.0E+07         0  20000000  40000000 
 
 
Treatment = Atra + Leic 
Application = Daily  subtracted from: 
 
Treatment     Application      Lower     Center      Upper 
Atra + Leic   Single        -7719624    -368754    6982117 
ATRa +Lenic   Daily        -29935182  -22584312  -15233441 
ATRa +Lenic   Single       -10991312   -3640441    3710429 
control       Daily         -9045311   -1694440    5656430 
control       Single        -5555510    1795361    9146232 
dmso control  Daily         -8776519   -1425648    5925222 
dmso control  Single        -3470284    3880587   11231458 
Linoleic      Daily        -14032942   -6682072     668799 
Linoleic      Single        -7750222    -399352    6951519 
Linolenic     Daily        -22496280  -15145409   -7794538 
Linolenic     Single        -9107172   -1756302    5594569 
 
Treatment     Application    -----+---------+---------+---------+- 
Atra + Leic   Single                    (---*--) 
ATRa +Lenic   Daily          (---*--) 
ATRa +Lenic   Single                   (--*---) 
control       Daily                    (---*---) 
control       Single                     (---*---) 
dmso control  Daily                     (--*---) 
dmso control  Single                      (---*---) 
Linoleic      Daily                  (---*--) 
Linoleic      Single                    (---*--) 
Linolenic     Daily              (--*---) 
Linolenic     Single                   (---*---) 
                             -----+---------+---------+---------+- 
                           -2.0E+07         0  20000000  40000000 
 
 
Treatment = Atra + Leic 
Application = Single  subtracted from: 
 
Treatment     Application      Lower     Center      Upper 
ATRa +Lenic   Daily        -29566429  -22215558  -14864687 
ATRa +Lenic   Single       -10622558   -3271688    4079183 
control       Daily         -8676557   -1325687    6025184 
control       Single        -5186756    2164115    9514985 
dmso control  Daily         -8407765   -1056895    6293976 
dmso control  Single        -3101530    4249341   11600211 
Linoleic      Daily        -13664189   -6313318    1037553 
Linoleic      Single        -7381469     -30598    7320273 
Linolenic     Daily        -22127526  -14776655   -7425785 
Linolenic     Single        -8738419   -1387548    5963323 
 
Treatment     Application    -----+---------+---------+---------+- 
ATRa +Lenic   Daily          (---*---) 
ATRa +Lenic   Single                   (--*---) 
control       Daily                     (--*---) 
control       Single                     (---*---) 
dmso control  Daily                     (--*---) 
dmso control  Single                      (---*---) 
Linoleic      Daily                  (---*---) 
Linoleic      Single                    (---*---) 
Linolenic     Daily              (---*--) 
Linolenic     Single                    (--*---) 
                             -----+---------+---------+---------+- 
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                           -2.0E+07         0  20000000  40000000 
 
 
Treatment = ATRa +Lenic 
Application = Daily  subtracted from: 
 
Treatment     Application     Lower    Center     Upper 
ATRa +Lenic   Single       11593000  18943870  26294741 
control       Daily        13539001  20889871  28240742 
control       Single       17028802  24379673  31730544 
dmso control  Daily        13807793  21158663  28509534 
dmso control  Single       19114028  26464899  33815769 
Linoleic      Daily         8551369  15902240  23253111 
Linoleic      Single       14834089  22184960  29535831 
Linolenic     Daily           88032   7438903  14789773 
Linolenic     Single       13477139  20828010  28178881 
 
Treatment     Application    -----+---------+---------+---------+- 
ATRa +Lenic   Single                              (--*---) 
control       Daily                                (--*---) 
control       Single                                 (--*---) 
dmso control  Daily                                (---*--) 
dmso control  Single                                  (--*---) 
Linoleic      Daily                             (---*---) 
Linoleic      Single                               (---*---) 
Linolenic     Daily                         (---*--) 
Linolenic     Single                               (--*---) 
                             -----+---------+---------+---------+- 
                           -2.0E+07         0  20000000  40000000 
 
 
Treatment = ATRa +Lenic 
Application = Single  subtracted from: 
 
Treatment     Application      Lower     Center     Upper 
control       Daily         -5404870    1946001   9296872 
control       Single        -1915068    5435802  12786673 
dmso control  Daily         -5136078    2214793   9565664 
dmso control  Single          170158    7521028  14871899 
Linoleic      Daily        -10392501   -3041630   4309241 
Linoleic      Single        -4109781    3241090  10591960 
Linolenic     Daily        -18855838  -11504968  -4154097 
Linolenic     Single        -5466731    1884140   9235010 
 
Treatment     Application    -----+---------+---------+---------+- 
control       Daily                      (---*---) 
control       Single                       (---*--) 
dmso control  Daily                      (---*---) 
dmso control  Single                        (---*--) 
Linoleic      Daily                    (--*---) 
Linoleic      Single                      (---*--) 
Linolenic     Daily                (--*---) 
Linolenic     Single                     (---*---) 
                             -----+---------+---------+---------+- 
                           -2.0E+07         0  20000000  40000000 
 
 
Treatment = control 
Application = Daily  subtracted from: 
 
Treatment     Application      Lower     Center     Upper 
control       Single        -3861069    3489802  10840672 
dmso control  Daily         -7082079     268792   7619663 
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dmso control  Single        -1775843    5575027  12925898 
Linoleic      Daily        -12338502   -4987631   2363240 
Linoleic      Single        -6055782    1295089   8645959 
Linolenic     Daily        -20801839  -13450969  -6100098 
Linolenic     Single        -7412732     -61861   7289010 
 
Treatment     Application    -----+---------+---------+---------+- 
control       Single                      (---*--) 
dmso control  Daily                     (---*---) 
dmso control  Single                       (---*--) 
Linoleic      Daily                   (---*--) 
Linoleic      Single                     (---*--) 
Linolenic     Daily               (--*---) 
Linolenic     Single                    (---*---) 
                             -----+---------+---------+---------+- 
                           -2.0E+07         0  20000000  40000000 
 
 
Treatment = control 
Application = Single  subtracted from: 
 
Treatment     Application      Lower     Center     Upper 
dmso control  Daily        -10571880   -3221009   4129861 
dmso control  Single        -5265645    2085226   9436097 
Linoleic      Daily        -15828303   -8477433  -1126562 
Linoleic      Single        -9545584   -2194713   5156158 
Linolenic     Daily        -24291641  -16940770  -9589899 
Linolenic     Single       -10902533   -3551663   3799208 
 
Treatment     Application    -----+---------+---------+---------+- 
dmso control  Daily                    (--*---) 
dmso control  Single                     (---*---) 
Linoleic      Daily                 (---*--) 
Linoleic      Single                   (---*---) 
Linolenic     Daily             (---*--) 
Linolenic     Single                   (--*---) 
                             -----+---------+---------+---------+- 
                           -2.0E+07         0  20000000  40000000 
 
 
Treatment = dmso control 
Application = Daily  subtracted from: 
 
Treatment     Application      Lower     Center     Upper 
dmso control  Single        -2044635    5306235  12657106 
Linoleic      Daily        -12607294   -5256423   2094447 
Linoleic      Single        -6324574    1026297   8377167 
Linolenic     Daily        -21070631  -13719761  -6368890 
Linolenic     Single        -7681524    -330653   7020217 
 
Treatment     Application    -----+---------+---------+---------+- 
dmso control  Single                       (---*--) 
Linoleic      Daily                   (--*---) 
Linoleic      Single                     (---*--) 
Linolenic     Daily              (---*---) 
Linolenic     Single                    (---*---) 
                             -----+---------+---------+---------+- 
                           -2.0E+07         0  20000000  40000000 
 
 
Treatment = dmso control 
Application = Single  subtracted from: 
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Treatment  Application      Lower     Center      Upper 
Linoleic   Daily        -17913529  -10562659   -3211788 
Linoleic   Single       -11630809   -4279939    3070932 
Linolenic  Daily        -26376867  -19025996  -11675125 
Linolenic  Single       -12987759   -5636889    1713982 
 
Treatment  Application    -----+---------+---------+---------+- 
Linoleic   Daily                (---*--) 
Linoleic   Single                  (---*---) 
Linolenic  Daily            (--*---) 
Linolenic  Single                  (--*---) 
                          -----+---------+---------+---------+- 
                        -2.0E+07         0  20000000  40000000 
 
 
Treatment = Linoleic 
Application = Daily  subtracted from: 
 
Treatment  Application      Lower    Center     Upper 
Linoleic   Single        -1068151   6282720  13633591 
Linolenic  Daily        -15814208  -8463338  -1112467 
Linolenic  Single        -2425101   4925770  12276641 
 
Treatment  Application    -----+---------+---------+---------+- 
Linoleic   Single                       (---*---) 
Linolenic  Daily                 (---*--) 
Linolenic  Single                       (--*---) 
                          -----+---------+---------+---------+- 
                        -2.0E+07         0  20000000  40000000 
 
 
Treatment = Linoleic 
Application = Single  subtracted from: 
 
Treatment  Application      Lower     Center     Upper 
Linolenic  Daily        -22096928  -14746057  -7395187 
Linolenic  Single        -8707821   -1356950   5993921 
 
Treatment  Application    -----+---------+---------+---------+- 
Linolenic  Daily              (---*--) 
Linolenic  Single                    (--*---) 
                          -----+---------+---------+---------+- 
                        -2.0E+07         0  20000000  40000000 
 
 
Treatment = Linolenic 
Application = Daily  subtracted from: 
 
Treatment  Application    Lower    Center     Upper 
Linolenic  Single       6038237  13389107  20739978 
 
Treatment  Application    -----+---------+---------+---------+- 
Linolenic  Single                           (---*--) 
                          -----+---------+---------+---------+- 
                        -2.0E+07         0  20000000  40000000 
 
 
Tukey Simultaneous Tests 
Response Variable Count 
All Pairwise Comparisons among Levels of Treatment*Application 
Treatment = Atra 
Application = Daily  subtracted from: 
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                           Difference       SE of           Adjusted 
Treatment     Application    of Means  Difference  T-Value   P-Value 
Atra          Single         17149352     2006892    8.545    0.0000 
Atra + Leic   Daily          18026465     2006892    8.982    0.0000 
Atra + Leic   Single         17657711     2006892    8.799    0.0000 
ATRa +Lenic   Daily          -4557847     2006892   -2.271    0.5865 
ATRa +Lenic   Single         14386023     2006892    7.168    0.0000 
control       Daily          16332024     2006892    8.138    0.0000 
control       Single         19821826     2006892    9.877    0.0000 
dmso control  Daily          16600816     2006892    8.272    0.0000 
dmso control  Single         21907052     2006892   10.916    0.0000 
Linoleic      Daily          11344393     2006892    5.653    0.0004 
Linoleic      Single         17627113     2006892    8.783    0.0000 
Linolenic     Daily           2881056     2006892    1.436    0.9686 
Linolenic     Single         16270163     2006892    8.107    0.0000 
 
 
Treatment = Atra 
Application = Single  subtracted from: 
 
                           Difference       SE of           Adjusted 
Treatment     Application    of Means  Difference  T-Value   P-Value 
Atra + Leic   Daily            877113     2006892     0.44    1.0000 
Atra + Leic   Single           508359     2006892     0.25    1.0000 
ATRa +Lenic   Daily         -21707199     2006892   -10.82    0.0000 
ATRa +Lenic   Single         -2763328     2006892    -1.38    0.9773 
control       Daily           -817327     2006892    -0.41    1.0000 
control       Single          2672474     2006892     1.33    0.9826 
dmso control  Daily           -548535     2006892    -0.27    1.0000 
dmso control  Single          4757700     2006892     2.37    0.5224 
Linoleic      Daily          -5804959     2006892    -2.89    0.2386 
Linoleic      Single           477761     2006892     0.24    1.0000 
Linolenic     Daily         -14268296     2006892    -7.11    0.0000 
Linolenic     Single          -879189     2006892    -0.44    1.0000 
 
 
Treatment = Atra + Leic 
Application = Daily  subtracted from: 
 
                           Difference       SE of           Adjusted 
Treatment     Application    of Means  Difference  T-Value   P-Value 
Atra + Leic   Single          -368754     2006892    -0.18    1.0000 
ATRa +Lenic   Daily         -22584312     2006892   -11.25    0.0000 
ATRa +Lenic   Single         -3640441     2006892    -1.81    0.8521 
control       Daily          -1694440     2006892    -0.84    0.9998 
control       Single          1795361     2006892     0.89    0.9996 
dmso control  Daily          -1425648     2006892    -0.71    1.0000 
dmso control  Single          3880587     2006892     1.93    0.7923 
Linoleic      Daily          -6682072     2006892    -3.33    0.1027 
Linoleic      Single          -399352     2006892    -0.20    1.0000 
Linolenic     Daily         -15145409     2006892    -7.55    0.0000 
Linolenic     Single         -1756302     2006892    -0.88    0.9997 
 
 
Treatment = Atra + Leic 
Application = Single  subtracted from: 
 
                           Difference       SE of           Adjusted 
Treatment     Application    of Means  Difference  T-Value   P-Value 
ATRa +Lenic   Daily         -22215558     2006892   -11.07    0.0000 
ATRa +Lenic   Single         -3271688     2006892    -1.63    0.9227 
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control       Daily          -1325687     2006892    -0.66    1.0000 
control       Single          2164115     2006892     1.08    0.9973 
dmso control  Daily          -1056895     2006892    -0.53    1.0000 
dmso control  Single          4249341     2006892     2.12    0.6846 
Linoleic      Daily          -6313318     2006892    -3.15    0.1489 
Linoleic      Single           -30598     2006892    -0.02    1.0000 
Linolenic     Daily         -14776655     2006892    -7.36    0.0000 
Linolenic     Single         -1387548     2006892    -0.69    1.0000 
 
 
Treatment = ATRa +Lenic 
Application = Daily  subtracted from: 
 
                           Difference       SE of           Adjusted 
Treatment     Application    of Means  Difference  T-Value   P-Value 
ATRa +Lenic   Single         18943870     2006892    9.439    0.0000 
control       Daily          20889871     2006892   10.409    0.0000 
control       Single         24379673     2006892   12.148    0.0000 
dmso control  Daily          21158663     2006892   10.543    0.0000 
dmso control  Single         26464899     2006892   13.187    0.0000 
Linoleic      Daily          15902240     2006892    7.924    0.0000 
Linoleic      Single         22184960     2006892   11.054    0.0000 
Linolenic     Daily           7438903     2006892    3.707    0.0451 
Linolenic     Single         20828010     2006892   10.378    0.0000 
 
 
Treatment = ATRa +Lenic 
Application = Single  subtracted from: 
 
                           Difference       SE of           Adjusted 
Treatment     Application    of Means  Difference  T-Value   P-Value 
control       Daily           1946001     2006892    0.970    0.9991 
control       Single          5435802     2006892    2.709    0.3246 
dmso control  Daily           2214793     2006892    1.104    0.9967 
dmso control  Single          7521028     2006892    3.748    0.0410 
Linoleic      Daily          -3041630     2006892   -1.516    0.9531 
Linoleic      Single          3241090     2006892    1.615    0.9274 
Linolenic     Daily         -11504968     2006892   -5.733    0.0003 
Linolenic     Single          1884140     2006892    0.939    0.9993 
 
 
Treatment = control 
Application = Daily  subtracted from: 
 
                           Difference       SE of           Adjusted 
Treatment     Application    of Means  Difference  T-Value   P-Value 
control       Single          3489802     2006892    1.739    0.8842 
dmso control  Daily            268792     2006892    0.134    1.0000 
dmso control  Single          5575027     2006892    2.778    0.2901 
Linoleic      Daily          -4987631     2006892   -2.485    0.4508 
Linoleic      Single          1295089     2006892    0.645    1.0000 
Linolenic     Daily         -13450969     2006892   -6.702    0.0001 
Linolenic     Single           -61861     2006892   -0.031    1.0000 
 
 
Treatment = control 
Application = Single  subtracted from: 
 
                           Difference       SE of           Adjusted 
Treatment     Application    of Means  Difference  T-Value   P-Value 
dmso control  Daily          -3221009     2006892   -1.605    0.9303 
dmso control  Single          2085226     2006892    1.039    0.9981 
Linoleic      Daily          -8477433     2006892   -4.224    0.0132 
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Linoleic      Single         -2194713     2006892   -1.094    0.9969 
Linolenic     Daily         -16940770     2006892   -8.441    0.0000 
Linolenic     Single         -3551663     2006892   -1.770    0.8715 
 
 
Treatment = dmso control 
Application = Daily  subtracted from: 
 
                           Difference       SE of           Adjusted 
Treatment     Application    of Means  Difference  T-Value   P-Value 
dmso control  Single          5306235     2006892    2.644    0.3588 
Linoleic      Daily          -5256423     2006892   -2.619    0.3725 
Linoleic      Single          1026297     2006892    0.511    1.0000 
Linolenic     Daily         -13719761     2006892   -6.836    0.0001 
Linolenic     Single          -330653     2006892   -0.165    1.0000 
 
 
Treatment = dmso control 
Application = Single  subtracted from: 
 
                        Difference       SE of           Adjusted 
Treatment  Application    of Means  Difference  T-Value   P-Value 
Linoleic   Daily         -10562659     2006892   -5.263    0.0010 
Linoleic   Single         -4279939     2006892   -2.133    0.6750 
Linolenic  Daily         -19025996     2006892   -9.480    0.0000 
Linolenic  Single         -5636889     2006892   -2.809    0.2755 
 
 
Treatment = Linoleic 
Application = Daily  subtracted from: 
 
                        Difference       SE of           Adjusted 
Treatment  Application    of Means  Difference  T-Value   P-Value 
Linoleic   Single          6282720     2006892    3.131    0.1534 
Linolenic  Daily          -8463338     2006892   -4.217    0.0134 
Linolenic  Single          4925770     2006892    2.454    0.4698 
 
 
Treatment = Linoleic 
Application = Single  subtracted from: 
 
                        Difference       SE of           Adjusted 
Treatment  Application    of Means  Difference  T-Value   P-Value 
Linolenic  Daily         -14746057     2006892   -7.348    0.0000 
Linolenic  Single         -1356950     2006892   -0.676    1.0000 
 
 
Treatment = Linolenic 
Application = Daily  subtracted from: 
 
                        Difference       SE of           Adjusted 
Treatment  Application    of Means  Difference  T-Value   P-Value 
Linolenic  Single         13389107     2006892    6.672    0.0001 
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